Lipella Pharmaceuticals Inc. Overview
Pro stress-test →Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications, targeting diseases with significant unmet needs where no approved drug therapies currently exist. As of March 30, 2026, the company filed for Chapter 11 bankruptcy restructuring in the U.S. Bankruptcy Court for the Western District of Pennsylvania, centered on a Section 363 asset sale to maximize value for creditors.
Strategic Profile
Pro stress-test →The company's principal assets include its intellectual property portfolio, the LP-310 and LP-10 clinical programs with associated FDA designations, U.S. Patent No. 12,138,345 covering the liposomal delivery platform, and a Pittsburgh manufacturing facility. The pipeline includes LP-10, a liposomal tacrolimus for hemorrhagic cystitis with FDA Orphan Drug Designation, and LP-310, a liposomal tacrolimus oral rinse for oral lichen planus, with LP-310 completing a Phase 2a trial across 27 patients in February 2025 and receiving FDA Expanded Access Program approval.
Competitive Landscape
Pro stress-test →Lipella operates in the niche market for rare disease treatments with unmet medical needs, competing against larger biopharmaceutical companies developing therapies for hemorrhagic cystitis and oral lichen planus. Direct competitors in liposomal delivery and rare disease therapeutics include other clinical-stage biotech firms, though Lipella's proprietary liposomal platform and orphan drug designations provide differentiation.
Industry Context
Lipella Pharmaceuticals Inc. operates in Orphan drug development for rare diseases.
Key facts
Founded: 2005 · Headquarters: Pittsburgh, US · Employees: Unknown · Revenue: $0 (pre-revenue) · Market cap: N/A